Literature DB >> 26125143

HAART and lungs: do HIV protease inhibitors impact cancer risk?

Thomas S Uldrick1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26125143      PMCID： PMC4493923          DOI： 10.1097/QAD.0000000000000644

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  10 in total

1.  Excess cancers among HIV-infected people in the United States.

Authors:  Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2015-02-06       Impact factor: 13.506

Review 2.  Cytochrome P450-mediated pulmonary metabolism of carcinogens: regulation and cross-talk in lung carcinogenesis.

Authors:  Sisko Anttila; Hannu Raunio; Jukka Hakkola
Journal:  Am J Respir Cell Mol Biol       Date:  2010-11-19       Impact factor: 6.914

3.  HIV as an independent risk factor for incident lung cancer.

Authors:  Keith Sigel; Juan Wisnivesky; Kirsha Gordon; Robert Dubrow; Amy Justice; Sheldon T Brown; Joseph Goulet; Adeel A Butt; Stephen Crystal; David Rimland; Maria Rodriguez-Barradas; Cynthia Gibert; Lesley S Park; Kristina Crothers
Journal:  AIDS       Date:  2012-05-15       Impact factor: 4.177

4.  Use of boosted protease inhibitors reduces Kaposi sarcoma incidence among male veterans with HIV infection.

Authors:  Marc A Kowalkowski; Jennifer R Kramer; Peter R Richardson; Insia Suteria; Elizabeth Y Chiao
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

5.  Cancer burden in the HIV-infected population in the United States.

Authors:  Meredith S Shiels; Ruth M Pfeiffer; Mitchell H Gail; H Irene Hall; Jianmin Li; Anil K Chaturvedi; Kishor Bhatia; Thomas S Uldrick; Robert Yarchoan; James J Goedert; Eric A Engels
Journal:  J Natl Cancer Inst       Date:  2011-04-11       Impact factor: 13.506

6.  The impact of HIV viral control on the incidence of HIV-associated anal cancer.

Authors:  Elizabeth Y Chiao; Christine M Hartman; Hashem B El-Serag; Thomas P Giordano
Journal:  J Acquir Immune Defic Syndr       Date:  2013-08-15       Impact factor: 3.731

7.  Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.

Authors:  Anne S Tsao; Timothy McDonnell; Stephen Lam; Joe B Putnam; Nebiyou Bekele; Waun Ki Hong; Jonathan M Kurie
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2003-07       Impact factor: 4.254

8.  Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.

Authors:  Joell J Gills; Jaclyn Lopiccolo; Junji Tsurutani; Robert H Shoemaker; Carolyn J M Best; Mones S Abu-Asab; Jennifer Borojerdi; Noel A Warfel; Erin R Gardner; Matthew Danish; M Christine Hollander; Shigeru Kawabata; Maria Tsokos; William D Figg; Patricia S Steeg; Phillip A Dennis
Journal:  Clin Cancer Res       Date:  2007-09-01       Impact factor: 12.531

9.  Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.

Authors:  M A Kowalkowski; M A Mims; R S Day; X L Du; W Chan; E Y Chiao
Journal:  Cancer Epidemiol       Date:  2014-06-16       Impact factor: 2.984

10.  A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors.

Authors:  Gideon M Blumenthal; Joell J Gills; Marc S Ballas; Wendy B Bernstein; Takefumi Komiya; Roopa Dechowdhury; Betsy Morrow; Hyejeong Root; Guinevere Chun; Cynthia Helsabeck; Seth M Steinberg; Jaclyn LoPiccolo; Shigeru Kawabata; Erin R Gardner; William D Figg; Phillip A Dennis
Journal:  Oncotarget       Date:  2014-09-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.